RGEN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RG

Mkt Cap

$11.14B

Volume

989.17K

Next Earnings

October 27th

Loading chart

RG

RGENRepligen Corp

RGEN

Pay with—

Available Balance0.00

RG

Mkt Cap

$11.14B

Volume

989.17K

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGRThe global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.GlobeNewswire Inc. · Oct 1, 2026

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.Zacks Investment Research · Sep 22, 2026

Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable BiomanufacturingThe global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.GlobeNewswire Inc. · Sep 15, 2026

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS StudiesNovartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.Zacks Investment Research · Sep 2, 2026

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.Zacks Investment Research · Sep 2, 2026

GSK to Advance mRNA Influenza Vaccine Into Phase III DevelopmentGSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.Zacks Investment Research · Sep 2, 2026

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset BidTeva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.Zacks Investment Research · Aug 31, 2026

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?Repligen (RGEN) reported Q2 2026 adjusted EPS of 54 cents, beating the consensus estimate of 45 cents, with revenues of $204.1 million up 12% year-over-year. The company raised its full-year 2026 revenue guidance to $813-$835 million and EPS guidance to $2.03-$2.09. Stock has gained 27.7% since the earnings report and received a Zacks Rank #1 (Strong Buy) rating.Zacks Investment Research · Aug 27, 2026

Global Sterile Bioprocess Filtration Market Set to Surge, Projected to Reach USD 31.33 Billion by 2034The global sterile bioprocess filtration market is projected to grow from USD 6.50 billion in 2025 to USD 31.33 billion by 2034, at a CAGR of 19.13%. Growth is driven by rising biopharmaceutical and vaccine demand, outsourcing to CMOs/CDMOs, and technological advancements. North America is expected to lead the market, with membrane filters dominating the product segment.GlobeNewswire Inc. · Jul 3, 2026

Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition OfferBio-Techne shares surged 20% after Merck KGaA announced a $73-per-share cash acquisition offer. The deal comes one week after activist investor Ananym Capital Management built a stake and pushed for a sale. Trading volume reached 51.3M shares, significantly above average. Merck KGaA expects to achieve over $150 million in annual cost synergies within three years.The Motley Fool · Jun 25, 2026

to start trading

RG

RGENRepligen Corp

RGEN

Pay with—

Available Balance0.00

Your PositionYou don't own any RGEN yet.

Related Tickers

Earnings